Radioimmunotherapy Consolidation using (131)I-Tositumomab for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

Despite initial responses to chemoimmunotherapy, relapse and minimal residual disease (MRD) remain major issues in treatment of CLL/SLL patients. We administered 131I-tositumomab to patients in CR or PR after induction chemotherapy. Toxicities and rate of PR to CR conversion and MRD elimination were...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Lymphoma
Autori principali: Shadman, Mazyar, Gopal, Ajay K., Kammerer, Britt, Becker, Pamela S., Maloney, David G., Pender, Barbara, Shustov, Andrei R., Press, Oliver W., Pagel, John M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4798884/
https://ncbi.nlm.nih.gov/pubmed/26133724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1067701
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi